Trial
|
Phase
|
Treatment
|
Primary Objective
|
---|
PERTAIN
|
II
|
Trastuzumab + Pertuzumab + AI vs Trastuzumab + AI
|
PFS
|
DETECT V/CHEVENDO
|
III
|
Trastuzumab + Pertuzumab + CT vs Trastuzumab + Pertuzumab + HTa
|
Safety
|
1303GCC
|
II
|
Trastuzumab + Pertuzumab vs Trastuzumab + Pertuzumab + Eribulin vs Trastuzumab + Pertuzumab + HT b
|
ORr
|
-
AI aromatase hinibitor, CT chemotherapy (docetaxel, paclitaxel, capecitabine, vinorelbine), aHT: Hormonal Therapy (tamoxifen, fulvestrant, letrozole, exemestane or anastrozole); bHT: Hormonal Therapy (anastrozolo or fulvestrant); PFS: Progression Free Survival; ORr: Overall Response rate